The cure rate of childhood acute lymphoblastic leukemia (ALL) has exceeded 90% in some
contemporary clinical trials. However, the dose intensity of conventional chemotherapy has …

We evaluated the administration of ARI-0001 cells (chimeric antigen receptor T cells
targeting CD19) in adult and pediatric patients with relapsed/refractory CD19+ …

Over the past 40 years, the 5-years-overall survival rate of pediatric cancer reached 75–
80%, and for acute lymphoblastic leukemia (ALL), exceeded 90%. Leukemia continues to be …

To identify the prognostic factors that are useful to improve central nervous system (CNS)
control in children with acute lymphoblastic leukemia (ALL), we analyzed the outcome of …

An updated strategy combining pediatric-based chemotherapy with risk-oriented allogeneic
hematopoietic cell transplantation (HCT) was evaluated in Philadelphia chromosome …

Patients harboring CRLF2-rearranged B-lineage acute lymphocytic leukemia (B-ALL) face a
5-year survival rate as low as 20%. While significant gains have been made to position …

Despite significant advances, outcomes for children with Down syndrome (DS, trisomy 21)
who develop acute lymphoblastic leukemia (ALL) remain poor. Reports of large DSALL …

Second-and third-generation tyrosine kinase inhibitors (TKI) play an important role in the
treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) …

Acute lymphoblastic leukemia (ALL) is the most common malignancy in children. Here, we
exploited the synergy between histone deacetylase inhibitors (HDACi) and cyclooxygenase …

Acute lymphoblastic leukemia (ALL) is the most common cancer in children and one of the
success stories in cancer therapeutics. Risk-directed therapy based on clinical, biologic and …